Status:
RECRUITING
Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions.
Lead Sponsor:
Centre Hospitalier Universitaire de Besancon
Conditions:
Benign Pancreatic Lesion
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The challenge for medical oncology is to develop plasma biomarkers that can detect the influence of the stroma on diagnosis, prognosis and response to chemotherapy. Today, there is no validated blood...
Eligibility Criteria
Inclusion
- Men and women ≥18 years
- Patient followed for benign pancreatic lesions:
- chronic pancreatitis acute pancreatitis at a distance from the acute episode (\> 4 weeks) with indication for echo-endoscopy for suspected precancerous pancreatic lesions (PanIN, TIPMP, mucinous cystadenomas) or other cystic lesions (serous cystadenomas)
Exclusion
- Malignant pancreatic tumor
- Legal incapacity or limited legal capacity
Key Trial Info
Start Date :
December 11 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06397846
Start Date
December 11 2024
End Date
June 1 2027
Last Update
December 27 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Besancon
Besançon, France
2
Hôpital Nord Franche-Comté
Montbéliard, France